NASDAQ:NDRA ENDRA Life Sciences (NDRA) Stock Price, News & Analysis → DON’T buy gold until you read this (From Sasco Gold LLC) (Ad) Free NDRA Stock Alerts $0.11 +0.01 (+9.80%) (As of 06/10/2024 ET) Add Compare Share Share Today's Range$0.11▼$0.1250-Day Range$0.09▼$0.3852-Week Range$0.07▼$2.79Volume28.46 million shsAverage Volume6.16 million shsMarket Capitalization$1.24 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends Get ENDRA Life Sciences alerts: Email Address ENDRA Life Sciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside7,042.9% Upside$8.00 Price TargetShort InterestHealthy0.96% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.45Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.48 out of 5 stars 3.5 Analyst's Opinion Consensus RatingENDRA Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageENDRA Life Sciences has only been the subject of 1 research reports in the past 90 days.Read more about ENDRA Life Sciences' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.96% of the float of ENDRA Life Sciences has been sold short.Short Interest Ratio / Days to CoverENDRA Life Sciences has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in ENDRA Life Sciences has recently increased by 2,517.50%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldENDRA Life Sciences does not currently pay a dividend.Dividend GrowthENDRA Life Sciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NDRA. Previous Next 2.0 News and Social Media Coverage News SentimentENDRA Life Sciences has a news sentiment score of -0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for ENDRA Life Sciences this week, compared to 1 article on an average week.Search Interest8 people have searched for NDRA on MarketBeat in the last 30 days. MarketBeat Follows4 people have added ENDRA Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ENDRA Life Sciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.80% of the stock of ENDRA Life Sciences is held by insiders.Percentage Held by InstitutionsOnly 1.19% of the stock of ENDRA Life Sciences is held by institutions.Read more about ENDRA Life Sciences' insider trading history. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of ENDRA Life Sciences is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ENDRA Life Sciences is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioENDRA Life Sciences has a P/B Ratio of 0.17. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about ENDRA Life Sciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Sasco Gold LLCDon’t make this retirement mistakeIf you have over $100,000 in your 401K or IRA… Then listen closely… Your money is rotting away, and you might not even realize it.Reserve your seat here. About ENDRA Life Sciences Stock (NASDAQ:NDRA)ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.Read More NDRA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NDRA Stock News HeadlinesJune 9 at 3:24 AM | americanbankingnews.comENDRA Life Sciences (NASDAQ:NDRA) PT Lowered to $8.00 at Ascendiant Capital MarketsJune 4, 2024 | businesswire.comENDRA Life Sciences Announces Pricing of $8.0 Million Public OfferingMay 22, 2024 | uk.investing.comENDRA meets with FDA on liver device clinical trial designMay 21, 2024 | msn.comR.I. will issue $80m bond for URI life sciences building this year, Speaker Shekarchi saysMay 20, 2024 | businesswire.comENDRA Provides Update Following In-person Meeting with FDAMay 15, 2024 | msn.comScience is making anti-aging progress. But do we want to live forever?May 15, 2024 | msn.comENDRA Life Sciences Inc. (NASDAQ:NDRA) Q1 2024 Earnings Call TranscriptMay 15, 2024 | finance.yahoo.comENDRA Life Sciences Inc (NDRA) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...May 14, 2024 | investorplace.comNDRA Stock Earnings: ENDRA Life Sciences Beats EPS for Q1 2024May 14, 2024 | businesswire.comENDRA Life Sciences Reports First Quarter 2024 Financial Results and Provides a Business UpdateMay 14, 2024 | omaha.comExact Sciences blood test for many cancers is going to patients this summerMay 9, 2024 | morningstar.comENDRA Life Sciences Inc Registered ShsMay 7, 2024 | finance.yahoo.comENDRA Life Sciences to Report First Quarter 2024 Financial Results on May 14, 2024May 7, 2024 | bizjournals.comLife sciences firm picks Triangle over Boston, Philly for 170-job facilityMay 2, 2024 | finanznachrichten.deENDRA Life Sciences Inc.: ENDRA Life Sciences Strengthens Intellectual Property with Issuance of Five New International PatentsMay 2, 2024 | msn.comLife's insiders: Decoding endosymbiosis with mathematicsMay 2, 2024 | businesswire.comENDRA Life Sciences Strengthens Intellectual Property with Issuance of Five New International PatentsApril 26, 2024 | reuters.comIndia's Glenmark Life Sciences posts lower Q4 profit as Red Sea crisis hurts API businessApril 12, 2024 | markets.businessinsider.comIRA Capital Acquires 237,000 Square-Foot Life Science/R&D Campus in ColumbusApril 1, 2024 | finance.yahoo.comENDRA Life Sciences Inc. (NASDAQ:NDRA) Q4 2023 Earnings Call TranscriptMarch 29, 2024 | finance.yahoo.comQ4 2023 ENDRA Life Sciences Inc Earnings CallMarch 28, 2024 | businesswire.comENDRA Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 27, 2024 | benzinga.comEarnings Preview For ENDRA Life SciencesMarch 21, 2024 | finance.yahoo.comENDRA Life Sciences to Report Fourth Quarter 2023 Financial Results on March 28, 2024March 14, 2024 | msn.comNuclera appoints Joseph Bertelsen as Chief Commercial OfficerSee More Headlines Receive NDRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ENDRA Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today6/10/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Electromedical equipment Sub-IndustryN/A Current SymbolNASDAQ:NDRA CUSIPN/A CIK1681682 Webwww.endrainc.com Phone(734) 335-0468FaxN/AEmployees21Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$8.00 Low Stock Price Target$8.00 Potential Upside/Downside+6,911.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.26) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,060,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-204.78% Return on Assets-153.48% Debt Debt-to-Equity RatioN/A Current Ratio1.04 Quick Ratio1.04 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.67 per share Price / Book0.17Miscellaneous Outstanding Shares11,040,000Free Float10,506,000Market Cap$1.26 million OptionableNot Optionable Beta1.06 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Francois Michelon (Age 58)Chairman, President & CEO Comp: $388.45kMs. Irina Pestrikova (Age 37)Senior Director of Finance & Secretary Comp: $185kMr. Michael Thornton Ph.D. (Age 56)Chief Technology Officer Comp: $279.24kDr. Jonathan Behr Ph.D.Co-FounderMr. Steve FreemanHuman Resources LeaderKey CompetitorsNuwellisNASDAQ:CHFSHelius Medical TechnologiesNASDAQ:HSDTTivic Health SystemsNASDAQ:TIVCViewRayNASDAQ:VRAYQViveve MedicalNASDAQ:VIVEView All Competitors NDRA Stock Analysis - Frequently Asked Questions Should I buy or sell ENDRA Life Sciences stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ENDRA Life Sciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" NDRA shares. View NDRA analyst ratings or view top-rated stocks. What is ENDRA Life Sciences' stock price target for 2024? 1 equities research analysts have issued 12-month price objectives for ENDRA Life Sciences' stock. Their NDRA share price targets range from $8.00 to $8.00. On average, they expect the company's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 7,042.9% from the stock's current price. View analysts price targets for NDRA or view top-rated stocks among Wall Street analysts. How have NDRA shares performed in 2024? ENDRA Life Sciences' stock was trading at $2.12 at the beginning of the year. Since then, NDRA stock has decreased by 94.7% and is now trading at $0.1120. View the best growth stocks for 2024 here. Are investors shorting ENDRA Life Sciences? ENDRA Life Sciences saw a increase in short interest in May. As of May 15th, there was short interest totaling 104,700 shares, an increase of 2,517.5% from the April 30th total of 4,000 shares. Based on an average trading volume of 184,100 shares, the short-interest ratio is currently 0.6 days. Approximately 1.0% of the company's stock are sold short. View ENDRA Life Sciences' Short Interest. When is ENDRA Life Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our NDRA earnings forecast. How were ENDRA Life Sciences' earnings last quarter? ENDRA Life Sciences Inc. (NASDAQ:NDRA) posted its quarterly earnings results on Tuesday, May, 14th. The company reported ($0.26) earnings per share (EPS) for the quarter. What other stocks do shareholders of ENDRA Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other ENDRA Life Sciences investors own include Advanced Micro Devices (AMD), Trevena (TRVN), VBI Vaccines (VBIV), Bionano Genomics (BNGO), OPKO Health (OPK), TherapeuticsMD (TXMD), electroCore (ECOR) and Genocea Biosciences (GNCA). When did ENDRA Life Sciences IPO? ENDRA Life Sciences (NDRA) raised $10 million in an initial public offering on Friday, February 3rd 2017. The company issued 2,000,000 shares at a price of $5.00-$5.50 per share. Dougherty & Company and Dawson James Securities served as the underwriters for the IPO. How do I buy shares of ENDRA Life Sciences? Shares of NDRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NDRA) was last updated on 6/11/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMoonshot Coins for the Current Crypto RunDid you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum s...Crypto 101 Media | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredMissed NVDA? Buy this AI stock NOWAfter Nvidia's record-breaking earnings surge, Wall Street is now selling the stock at the fastest pace in sev...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ENDRA Life Sciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ENDRA Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
